Nucleotide analogues as inhibitors of SARS‐CoV Polymerase
Abstract SARS‐CoV‐2, a member of the coronavirus family, has caused a global public health emergency. Based on our analysis of hepatitis C virus and coronavirus replication, and the molecular structures and activities of viral inhibitors, we previously reasoned that the FDA‐approved hepatitis C drug...
Main Authors: | Jingyue Ju, Xiaoxu Li, Shiv Kumar, Steffen Jockusch, Minchen Chien, Chuanjuan Tao, Irina Morozova, Sergey Kalachikov, Robert N. Kirchdoerfer, James J. Russo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-12-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.674 |
Similar Items
-
Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity
by: Xuanting Wang, et al.
Published: (2022-06-01) -
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
by: Ujjwal Neogi, et al.
Published: (2020-04-01) -
Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity
by: Abraham Madariaga-Mazón, et al.
Published: (2022-01-01) -
A Systematic Study on the Optimal Nucleotide Analogue Concentration and Rate Limiting Nucleotide of the SARS-CoV-2 RNA-Dependent RNA Polymerase
by: Hasan Vatandaslar
Published: (2022-07-01) -
Non-Nucleotide RNA-Dependent RNA Polymerase Inhibitor That Blocks SARS-CoV-2 Replication
by: Milan Dejmek, et al.
Published: (2021-08-01)